Prognostic impact of urine cyclic AMP levels in patients with chronic kidney disease.
Aquaporin 2
Arginine vasopressin
cAMP
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
06
07
2022
accepted:
06
08
2022
pubmed:
24
8
2022
medline:
19
11
2022
entrez:
23
8
2022
Statut:
ppublish
Résumé
Urine cyclic adenosine monophosphate (cAMP) is a biomarker to assess the residual function of the collecting duct in the kidney. Prognostic implication of urine cAMP levels in patients with chronic kidney disease (CKD) remains unknown. Patients who were followed at our specific outpatient clinic to treat their CKD between December 2015 and December 2019 were included in this prospective study. The impact of urine cAMP levels on the composite of dialysis administration, cardiovascular death, and doubling of serum creatinine concentration was investigated. A total of 106 patients (median 72 years old, 80 men, and median estimated glomerular filtration rate 28.4 mL/min/1.73 m A lower urine cAMP is an independent predictor of renal deterioration and cardiovascular death in patients with CKD.
Sections du résumé
BACKGROUND
BACKGROUND
Urine cyclic adenosine monophosphate (cAMP) is a biomarker to assess the residual function of the collecting duct in the kidney. Prognostic implication of urine cAMP levels in patients with chronic kidney disease (CKD) remains unknown.
METHODS
METHODS
Patients who were followed at our specific outpatient clinic to treat their CKD between December 2015 and December 2019 were included in this prospective study. The impact of urine cAMP levels on the composite of dialysis administration, cardiovascular death, and doubling of serum creatinine concentration was investigated.
RESULTS
RESULTS
A total of 106 patients (median 72 years old, 80 men, and median estimated glomerular filtration rate 28.4 mL/min/1.73 m
CONCLUSIONS
CONCLUSIONS
A lower urine cAMP is an independent predictor of renal deterioration and cardiovascular death in patients with CKD.
Identifiants
pubmed: 35999301
doi: 10.1007/s10157-022-02264-3
pii: 10.1007/s10157-022-02264-3
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Cyclic AMP
E0399OZS9N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1194-1199Informations de copyright
© 2022. The Author(s), under exclusive licence to The Japanese Society of Nephrology.
Références
Noda Y, Sasaki S. Updates and perspectives on aquaporin-2 and water balance disorders. Int J Mol Sci. 2021;22:12950.
doi: 10.3390/ijms222312950
pubmed: 34884753
pmcid: 8657825
Bricker NS, Dewey RR, Lubowitz H, Stokes J, Kirkensgaard T. Observations on the concentrating and diluting mechanisms of the diseased kidney. J Clin Invest. 1959;38:516–23.
doi: 10.1172/JCI103829
pubmed: 13641402
pmcid: 293187
Kakeshita K, Koike T, Imamura T, Fujioka H, Yamazaki H, Kinugawa K. Altered arginine vasopressin-cyclic AMP-aquaporin 2 pathway in patients with chronic kidney disease. Clin Exp Nephrol. 2022. https://doi.org/10.1007/s10157-022-02220-1 .
doi: 10.1007/s10157-022-02220-1
pubmed: 35999301
Sholokh A, Klussmann E. Local cyclic adenosine monophosphate signalling cascades-roles and targets in chronic kidney disease. Acta Physiol (Oxf). 2021;232: e13641.
doi: 10.1111/apha.13641
Lee MJ, Chang TI, Lee J, Kim YH, Oh KH, Lee SW, et al. Urine osmolality and renal outcome in patients with chronic kidney disease: results from the KNOW-CKD. Kidney Blood Press Res. 2019;44:1089–100.
doi: 10.1159/000502291
pubmed: 31505490
Tabibzadeh N, Wagner S, Metzger M, Flamant M, Houillier P, Boffa JJ, et al. Fasting urinary osmolality, CKD progression, and mortality: a prospective observational study. Am J Kidney Dis. 2019;73:596–604.
doi: 10.1053/j.ajkd.2018.12.024
pubmed: 30777634
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
doi: 10.1053/j.ajkd.2008.12.034
pubmed: 19339088
Olsen TS, Hansen HE. Ultrastructure of medullary tubules in ischemic acute tubular necrosis and acute interstitial nephritis in man. APMIS. 1990;98:1139–48.
doi: 10.1111/j.1699-0463.1990.tb05046.x
pubmed: 2282209
Rodionova EA, Kuznetsova AA, Shakhmatova EI, Prutskova N, Nielsen S, Holtbäck U, et al. Urinary aquaporin-2 in children with acute pyelonephritis. Pediatr Nephrol. 2006;21:361–7.
doi: 10.1007/s00467-005-2101-8
pubmed: 16382324
Kakeshita K, Koike T, Imamura T, Fujioka H, Yamazaki H, Kinugawa K. Expression of aquaporin-2 in the collecting duct and responses to tolvaptan. CEN Case Rep. 2021;10:69–73.
doi: 10.1007/s13730-020-00518-1
pubmed: 32779125
Wilson DR. Pathophysiology of obstructive nephropathy. Kidney Int. 1980;18:281–92.
doi: 10.1038/ki.1980.138
pubmed: 7007707
Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J. 2014;78:2240–9.
doi: 10.1253/circj.CJ-14-0244
pubmed: 24954239